


Thalidomide-PEG2-C2-NH2 TFA

Cat. No.:	HY-129703A
CAS No.:	2097509-36-7
Molecular Formula:	C ₂₁ H ₂₅ F ₃ N ₄ O ₈
Molecular Weight:	518.44
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (192.89 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9289 mL	9.6443 mL	19.2886 mL
	5 mM	0.3858 mL	1.9289 mL	3.8577 mL
	10 mM	0.1929 mL	0.9644 mL	1.9289 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Thalidomide-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology^[1].

IC₅₀ & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang Z, et al. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. J Med Chem. 2019 Sep 12;62(17):8152-8163.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA